NCT07625189 EUS-Guided Ablation (RFA and MWA) for Pancreatic and Other Gastrointestinal Lesions Registry
| NCT ID | NCT07625189 |
| Status | Recruiting |
| Phase | — |
| Sponsor | West Virginia University |
| Condition | RFA |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-03-10 |
| Primary Completion | 2028-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2026-03-10 with a primary completion date of 2028-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single-center, investigator-initiated, prospective observational registry that will collect longitudinal clinical data on adult patients (≥18 years) undergoing endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) or microwave ablation (MWA) for pancreatic and other gastrointestinal/hepatobiliary lesions as part of routine clinical care. The registry will not alter standard-of-care management. Data will be abstracted from the medical record and routine clinical systems. Primary outcomes include change in target lesion size on clinically obtained imaging and overall survival following ablation. Secondary outcomes include changes in tumor biomarkers, adverse events, non-target lesion changes, and patient-reported symptoms.
Eligibility Criteria
Inclusion Criteria: * Adults ≥ 18 years of age. * Diagnosis of a pancreatic premalignant lesion or malignancy, and other gastrointestinal or hepatobiliary lesion for which EUS-guided ablation is planned as part of standard clinical care. * At least one clinically identified target lesion for which RFA or MWA is performed. Exclusion Criteria: * In the judgment of the treating clinician, inclusion in the registry would not be appropriate * The individual is expected to be unable to complete routine clinical follow-up.
Contact & Investigator
Shailendra Singh, MD
PRINCIPAL INVESTIGATOR
West Virginia University
Frequently Asked Questions
Who can join the NCT07625189 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying RFA. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07625189 currently recruiting?
Yes, NCT07625189 is actively recruiting participants. Contact the research team at zh00027@mix.wvu.edu for enrollment information.
Where is the NCT07625189 trial being conducted?
This trial is being conducted at Morgantown, United States.
Who is sponsoring the NCT07625189 clinical trial?
NCT07625189 is sponsored by West Virginia University. The principal investigator is Shailendra Singh, MD at West Virginia University. The trial plans to enroll 50 participants.